Skip to main content

Advertisement

Table 1 Summary of HVIGI studies

From: Study protocol: a double blind randomised control trial of high volume image guided injections in Achilles and patellar tendinopathy in a young active population

Study Intervention Control +/− VAS
Pain
+/− Function eg VISA-A/P
Achilles tendinopathy
 Chan 2008 [68] N = 30
10ml 0.5% Bupivacaine 25mg Hydrocortisone 40ml N Saline
No control N = 21
@4w
-51mm
N = 21
@4w VISA-A +31.4
 Humphrey 2010 [69] N = 11
10ml 0.5% Bupivacaine 25mg Hydrocortisone
40ml N Saline
No Control   @3w VISA-A +38 (P < 0.001)
NeoVasc reduced 3 to 1.1
Tendon diam 8.7 to 7.6mm
 Restighini 2012 [70] N = 32
5ml 1% Lidocaine
25mg Hydrocortisone
Up to 40ml N Saline
No Control @4w
-34mm
@3m
-37mm
@4w VISA-A +26.5
@3m VISA-A +28.7
NeoVasc reduced 2 to 0.2
 Maffuli 2013 [71] N = 94
10ml 0.5% Bupivacaine 25mg Aprotinin
up to 40mls N saline
No Control    @12m VISA-A +32.9
(P = 0.003)
 Wheeler 2014 [72] N = 16
10ml 1% Lidocaine 40ml Saline
No Control @347d −6.1/10 (P = 0.001) @347d VISA-A + 41
(P = 0.001)
 Wheeler 2016 [73] N = 34
10ml 1% Lidocaine + 40ml Saline
V 10ml 1% Lidocaine + 20ml Saline
No Control @281d −4.6/10 (P < 0.01) 50ml Group @281v271d VISA-A +33.4 and + 6.94 in 50ml and 30ml group respectively (P = 0.002)
Patellar tendinopathy
 Crisp 2008 [74] N = 9
10ml 0.5% Bupivacaine
25mg Hydrocortisone 40ml N Saline
No control @2w
Sig. improve.
@9m VISA-P +22
 Morton 2014 [22] N = 20
10 ml 0.5% Bupivacaine 25mg hydrocortisone 30ml N saline
No Control   @12w–9m
VISA-P +19
(P < 0.01)
 Maffuli 2016 [75] N = 44
10ml 0.5% Bupivacaine 62500 IU Aprotinin
40ml N saline
No Control @15m
-63mm
(P = 0.01)
@15m VISA-P +29.3
(P = 0.003)
  1. VISA-A Victoria Institute of Sport Assessment-Achilles, VISA-P Victoria Institute of Sport Assessment-Patella, VAS Visual Analogue Scale, NeoVasc Grade of Neovasculatity, IU International Units, m months, w weeks, d days